# Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

> **NCT00000923** · NA · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 110 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Lamivudine
- **DRUG:** Stavudine
- **DRUG:** Zidovudine
- **DRUG:** Didanosine
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT00000923
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 110 (—)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000923, "Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00000923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*